FPA008 (anti-CSF1r) + PD-1 Inhibitor Deal Announced (Trial Already Started)

[DK37]

This co-development deal announced between BMS (maker of Opdivo (nivolumab)) and Five Prime Therapeutics is a PD-1 combo trial I am watching closely & crossing fingers for MSS CRC. It combines a PD-1 inhibitor with a drug called FPA008 which blocks something called CSF1R.

http://www.businesswire.com/news/home/2 ... h9lf75Aw20

Scientists hope that blocking CSF1R would remove immunosupression from the "tumor microenvironment" - and make "cold tumors" (e.g. MSS-CRC tumors are "cold") more "hot" i.e. able to be attacked by the immune system. This is a subject I wrote about in a general way here: http://fightcolorectalcancer.org/resear ... ot-part-1/

Here is the link to the Phase 1 trial. As far as I know it is open to both MSI and MSS CRC patients. It just started in TX - they are planning a big trial so I am sure multiple additional sites will be opening soon.
https://clinicaltrials.gov/ct2/show/NCT ... 008&rank=1

This is a Phase 1 trial so no clinical data that it works yet - but from a purely scientific point of view, I think worthy of keeping a very close eye on!

-DK

[Ceebo]

Thanks for the information, Tom! My DH is currently taking the TAS-102 drug and is tolerating it well so far, but we continue to look for new options in the future!

[ieowi]

I really don't know what can we do without you DK37. Thank you very much for keeping us up to date with these trials.

[Nik Colon]

Awesome! Thanks!

[Steph20021]

Yes thank you for sharing your knowledge and educating me.